Merck KGaA (FRA:MRK) received a €115.00 ($141.98) price target from stock analysts at UBS Group in a report issued on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target indicates a potential upside of 47.28% from the company’s current price.
MRK has been the subject of several other reports. Nord/LB restated a “neutral” rating on shares of Merck KGaA in a research report on Wednesday, December 27th. Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, March 7th. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, January 4th. Sanford C. Bernstein set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Finally, Kepler Capital Markets set a €106.00 ($130.86) price objective on Merck KGaA and gave the stock a “buy” rating in a research report on Monday. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck KGaA has an average rating of “Hold” and a consensus target price of €101.77 ($125.65).
Shares of Merck KGaA (FRA:MRK) opened at €78.08 ($96.40) on Wednesday. Merck KGaA has a 12-month low of €76.60 ($94.57) and a 12-month high of €115.00 ($141.98). The stock has a market cap of $10,040.00 and a P/E ratio of 13.06.
COPYRIGHT VIOLATION NOTICE: “Merck KGaA (MRK) PT Set at €115.00 by UBS Group” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/16/merck-kgaa-mrk-pt-set-at-115-00-by-ubs-group.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.